You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪医药(06996.HK)夥药明生物(02269.HK)等加快抗体偶联药物研发生产
阿思达克 02-01 15:05
德琪医药(06996.HK)公布,与药明生物(02269.HK)及合全药业三方达成战略合作,共同加快抗体偶联药物(ADC)的研发及生产,通过「平台+自研」并行策略,以提高ADC药物等早期研发项目的孵化效率。

药明生物与合全药业将为德琪医药ADC药物开发提供产品中间体的规模放大、工艺开发和GMP生产服务,其中德琪医药专注於抗体偶联药物的核心单克隆抗体(mAb)的研发;合全药业专注於连接体和有效载荷的GMP生产;药明生物专注mAb、生物偶联和成品冻乾工艺开发,并以GMP标准生产偶联原液和冻乾制剂。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account